Gladstone, Xyphos target universal CARs to latent HIV

Gladstone, Xyphos target latent HIV with universal CARs to control safety, prevent escape

Xyphos teamed up with the Gladstone Institutes to direct the company’s universal CAR Ts to cells latently infected with HIV, addressing several of the challenges CAR Ts have faced in the indication.

Major barriers to developing CAR Ts outside oncology include cytotoxicity and high costs. For HIV, an additional challenge has been preventing viral escape (see “CAR

Read the full 570 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers